SAB Biotherapeutics (SABS) Preferred Stock Liabilities (2021)
SAB Biotherapeutics (SABS) posted Preferred Stock Liabilities of $116.15 million for Q3 2021, up 13.7% from the prior quarter.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Preferred Stock Liabilities (2021) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | - |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | - |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | - |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | - |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | - |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | - |
| 10 | SAB Biotherapeutics | 264.67 Mn | 264.67 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 116.15 Mn |
| Jun 30, 2021 | 102.19 Mn |
| Mar 31, 2021 | 104.39 Mn |
API Access
SAB Biotherapeutics Preferred Stock Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=SABS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "preferred-stock-liabilities", "ticker": "SABS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=SABS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();